And in chronic lymphocytic leukemia, after the appearance of acquired resistance of venetoclax, the inhibitor of B-cell lymphoma-2 (BCL-2), mitochondrial mass of cancer cells and OXPHOS increased and OXPHOS inhibition rescued the venetoclax sensitivity (Guieze et al., 2019). This evidence concerns the gene BCL2 and cancer.